Why Early Response Matters in Alopecia Areata: Setting Expectations and Recognizing Meaningful Progress

This video is sponsored by Sun Pharma. Its content is editorially independent of the sponsor.

In this episode of Topical Conversations, Meena Singh, MD, and Terry Faleye, PA-C, discuss why speed of disease control has become an increasingly important consideration in the management of alopecia areata (AA). As treatment options continue to expand, they explore how earlier signs of response can influence patient confidence, improve treatment persistence, and reshape conversations about what patients can expect during therapy. Using deuruxolitinib as an example, they highlight how evolving efficacy data have changed both provider expectations and the patient experience.

The importance of speed in a disease with significant psychosocial impact

The treatment landscape for moderate to severe AA has changed substantially with the availability of multiple FDA-approved Janus kinase (JAK) inhibitors. While efficacy remains the primary goal, Dr Singh and Faleye emphasize that when patients begin to see improvement can be nearly as important as how much improvement they ultimately achieve.

For many patients, AA develops suddenly and is accompanied by considerable emotional distress. Faleye notes that many individuals present with little understanding of the disease itself, making education about its chronic nature and treatment course an essential part of the initial visit.

The ability to demonstrate visible improvement early in treatment can provide reassurance during what is often an emotionally challenging period. Both speakers describe how even small signs of regrowth can reinforce that treatment is working, helping patients remain engaged and optimistic rather than becoming discouraged after months without visible progress.

How earlier responses are changing treatment conversations

Historically, clinicians often counseled patients that meaningful regrowth might not occur for many months, if at all. Dr Singh notes that this has changed with newer therapies.

She discusses how clinical studies of deuruxolitinib demonstrated statistically significant, clinically meaningful hair regrowth as early as 8 weeks, despite the primary efficacy endpoint occurring later in treatment. In her own practice, she has observed patients with extensive scalp involvement experience dramatic improvement within the first few months of therapy, fundamentally changing how she frames expectations at treatment initiation.

Faleye similarly points to the secondary efficacy assessments at weeks 8, 12, 16, and 20 as particularly meaningful from a clinical perspective. Seeing evidence of earlier response provides reassurance to both patients and clinicians that therapy is moving in the right direction.

She also shares the experience of a patient who had an inadequate response to a different JAK inhibitor but later achieved substantial regrowth after initiating deuruxolitinib, reinforcing her confidence in discussing treatment expectations with appropriate patients.

Clinical success and patient-defined success are not always the same

One of the recurring themes throughout the discussion is that clinicians and patients often define treatment success differently.

Dr Singh notes that patients may become excited by the appearance of fine vellus hairs, even though these early changes would not yet represent meaningful terminal hair regrowth from a clinical trial perspective. Nevertheless, these visible signs frequently provide patients with reassurance that treatment is working.

Faleye agrees, emphasizing that these seemingly modest improvements often have an outsized effect on treatment adherence. While clinicians recognize that additional regrowth is needed to achieve optimal outcomes, patients may view these early changes as important milestones that motivate them to continue therapy.

Recognizing early indicators of response

The speakers encourage clinicians to look beyond scalp hair counts alone when assessing early treatment response.

Dr Singh notes that eyebrow, eyelash, and beard regrowth, even when limited, can represent meaningful early signs that therapy is having an effect. Likewise, a noticeable reduction in hair shedding may precede visible regrowth and can be an encouraging indicator to discuss during follow-up visits.

Faleye adds that improvements that may seem minor clinically can carry tremendous significance for individual patients. She recalls an older patient whose primary concern was beard patchiness; seeing early beard regrowth substantially improved the patient's outlook despite relatively modest overall changes.

Recognizing and reinforcing these individualized treatment successes can strengthen the therapeutic relationship and support continued adherence while more substantial regrowth develops.

Early treatment may help change the long-term trajectory

The discussion also highlights the importance of identifying and treating AA promptly whenever appropriate.

Faleye observes that patients with longstanding disease may be less likely to pursue treatment because of previous disappointments or because they remain unaware that newer therapeutic options are available. At the same time, these individuals can present greater treatment challenges than patients who begin therapy earlier in the disease course.

Both speakers emphasize the importance of educating patients about advances in AA management and encouraging timely intervention when indicated.

A changing patient experience

Perhaps one of the most meaningful changes, according to Dr Singh, is the transformation she sees in patients between their initial consultation and early follow-up visits. Patients who begin experiencing regrowth within the first few months often return with noticeably greater optimism and confidence, changing the tone of subsequent visits.

For both clinicians, the availability of therapies capable of producing earlier, meaningful responses has altered not only treatment strategies but also the overall patient experience. They conclude that recognizing early improvements, setting realistic expectations, and initiating effective therapy promptly can all contribute to better long-term engagement and outcomes for patients with AA.